NAD Refers Beyond Air to Regulators Over Claims
The advertising self-regulatory body will refer the company's LungFit PH marketing claims to the appropriate regulatory authorities after it declined to participate.
Updated on Nov. 18, 2026 in Asthma

BBB National Programs' National Advertising Division will refer Beyond Air, Inc. to the appropriate regulatory authorities after the company informed NAD it would not participate in the advertising industry's self-regulatory process. The referral follows a Fast-Track SWIFT challenge filed by competitor Vero Biotech Inc. over claims about Beyond Air's LungFit PH system.
Why it matters
The referral moves a competitive advertising dispute in the inhaled nitric oxide market out of industry self-regulation and toward government oversight. It shows how a company's refusal to take part in self-regulation can lead to escalation for contested marketing claims.
The matter was filed as a single-issue Fast-Track SWIFT challenge by Vero Biotech Inc., and the referral was made under Section 2.1(I)(3) of the NAD/NARB Procedures. The extraction does not state whether regulators have accepted the referral or what timeline they will follow.
The players
National Advertising Division (NAD)
The National Advertising Division is the self-regulatory body of BBB National Programs that reviews national advertising claims for accuracy and refers unresolved disputes to government agencies.
Beyond Air, Inc.
Beyond Air is a medical device company that develops the LungFit PH inhaled nitric oxide system for treating pulmonary hypertension in newborns and adults.
The details
Vero Biotech Inc. challenged Beyond Air's claims that LungFit PH has no or materially less logistical dependency and burden than Vero's GENOSYL Delivery System, and Beyond Air declined to take part in the self-regulatory process. As a result, NAD will refer the matter to the appropriate regulatory authorities.
Timeline
November 18, 2026: NAD announced the referral of Beyond Air to regulatory authorities.
Regulatory Context
Under Section 2.1(I)(3) of the NAD/NARB Procedures, companies that decline to participate in self-regulatory review can be referred to government agencies, a step that places this medical-device marketing dispute in the formal regulatory system. The case is an example of how industry self-regulation in the inhaled nitric oxide market can hand off competitor complaints to federal oversight.
Patients and clinicians who use or are considering LungFit PH may see the marketing claims at the center of this dispute reviewed by regulators. The referral does not change how the device is prescribed or available.
The takeaway
Advertising claims about medical devices can move from competitor challenges to government review when a company declines industry self-regulation. Readers evaluating treatment marketing should check claims against regulatory and clinical sources.
Further reading
For related coverage of respiratory treatments, see Asthma.
Source note: This article includes information reported by The Manila times.






